focused on modulating TdT gene expression using PNA's technology.[57] They employed short PNA conjugates stabilized with D‐octarginine to target the TdT gene in Molt‐4 cells, which are derived from human acute lymphoblastic leukemia. The gene discussed is DNTT; the disease is acute lymphoblastic leukemia.